Business context and reporting period
Important identity discrepancy: The supplied filing is Wealthbridge Acquisition Limited’s Form 10-Q for the quarter ended March 31, 2019—not a filing by Scienjoy Holding Corp. Wealthbridge was a blank-check company seeking a business combination, with an intended focus on China’s air transportation and aviation industry. Its activities were formation, its February 2019 IPO, and target identification; it had no operating revenue.
Financial results and position
- Quarterly results: Operating costs were $150,058. Trust-account interest income was $178,921 and unrealized gains were $2,184, resulting in net income of $31,047. Basic and diluted loss per share was $0.07, after excluding $159,445 of income attributable to shares subject to possible redemption.
- Cash flow: Operating activities used $139,102; investing activities used $57.5 million, principally for the trust account; financing activities provided $58.1 million. Cash outside the trust account rose to $538,177.
- Assets and liquidity: Total assets were $58.25 million, including $57.68 million in trust-account securities and $538,177 of cash outside the trust. Trust assets were substantially invested in U.S. Treasury bills. The outside cash was intended to fund target search and transaction expenses.
- Liabilities and equity: Total liabilities were $2.47 million, including $415,641 owed under a non-interest-bearing related-party note and $2.01 million of deferred underwriting fees payable upon a business combination. Another $50.78 million for 5,062,074 potentially redeemable shares was classified as temporary equity. Shareholders’ equity was $5.00 million.
- Revenue and margins: No operating revenue was reported, so operating margins are not meaningful. The filing does not present a comparable prior-year-quarter income statement; balance-sheet comparisons are with December 31, 2018.
Material changes and unusual items
In February, the company completed an IPO of 5.75 million units, including full exercise of the over-allotment option, and sold 270,000 private units. Gross proceeds were $57.5 million from public units and $2.7 million from private units; $57.5 million was placed in the trust account. IPO-related costs totaled $4.42 million. Trust-account securities and redeemable shares were therefore newly recorded at March 31, 2019. The quarter’s positive net income reflects trust-account earnings despite an operating loss.
Outlook, risks and contingencies
- The company had until February 8, 2020 to complete a business combination, with up to three optional three-month extensions, each requiring a $575,000 trust deposit. If it failed to complete a transaction within the permitted period, it would have to redeem public shares and liquidate; warrants and rights could expire worthless.
- Management expected to use substantially all trust funds for a business combination and said it did not expect to need additional funds before then. It cautioned that higher-than-expected search or diligence costs could leave insufficient working capital; additional financing might be needed to complete a transaction.
- The Sponsor agreed to cover certain third-party claims that reduce trust funds below $10 per share, subject to exceptions, including claims where waivers are unenforceable. The filing notes that trust distributions could nevertheless be less than $10 per share.
- The company reported no long-term debt or off-balance-sheet arrangements, no legal proceedings, and no material changes to the risk factors in its 2018 Form 10-K. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Investor verification points
- Confirm the issuer identity: this filing names Wealthbridge Acquisition Limited, not Scienjoy Holding Corp.
- Verify the cash and balance-sheet figures against the filed statements: the balance sheet lists December 31, 2018 cash of $52,937, while its total-current-assets line shows $52,927.
- Review the terms, timing, and funding requirements for the business-combination deadline and any extensions.
- Assess redeemable-share, trust-account, Sponsor-indemnity, and potential additional-financing risks.
- Review the related-party note, Sponsor service fees, deferred underwriting fees, and potential dilution from warrants, rights, and the underwriter’s unit purchase option.